O	0	12	Coexpression	Coexpression	NN	B-NP
O	13	15	of	of	IN	B-PP
O	16	24	vascular	vascular	JJ	B-NP
O	25	36	endothelial	endothelial	JJ	I-NP
O	37	43	growth	growth	NN	I-NP
O	44	50	factor	factor	NN	I-NP
O	51	54	and	and	CC	O
O	55	58	p53	p53	NN	B-NP
O	59	66	protein	protein	NN	I-NP
O	67	69	in	in	IN	B-PP
B-Cancer	70	78	squamous	squamous	JJ	B-NP
I-Cancer	79	83	cell	cell	NN	I-NP
I-Cancer	84	93	carcinoma	carcinoma	NN	I-NP
O	94	96	of	of	IN	B-PP
O	97	100	the	the	DT	B-NP
B-Organ	101	110	esophagus	esophagus	NN	I-NP
O	110	111	.	.	.	O

O	112	121	OBJECTIVE	OBJECTIVE	NN	B-NP
O	121	122	:	:	:	O
O	123	126	p53	p53	NN	B-NP
O	127	132	plays	play	VBZ	B-VP
O	133	134	a	a	DT	B-NP
O	135	139	role	role	NN	I-NP
O	140	142	in	in	IN	B-PP
B-Cancer	143	148	tumor	tumor	NN	B-NP
O	149	161	angiogenesis	angiogenesis	NN	I-NP
O	161	162	,	,	,	O
O	163	166	and	and	CC	O
O	167	175	vascular	vascular	JJ	B-NP
O	176	187	endothelial	endothelial	JJ	I-NP
O	188	194	growth	growth	NN	I-NP
O	195	201	factor	factor	NN	I-NP
O	202	203	(	(	(	O
O	203	207	VEGF	VEGF	NN	B-NP
O	207	208	)	)	)	O
O	209	214	plays	play	VBZ	B-VP
O	215	216	a	a	DT	B-NP
O	217	220	key	key	JJ	I-NP
O	221	225	role	role	NN	I-NP
O	226	228	in	in	IN	B-PP
B-Cancer	229	234	tumor	tumor	NN	B-NP
O	235	247	angiogenesis	angiogenesis	NN	I-NP
O	247	248	.	.	.	O

O	249	252	The	The	DT	B-NP
O	253	256	aim	aim	NN	I-NP
O	257	259	of	of	IN	B-PP
O	260	263	the	the	DT	B-NP
O	264	271	present	present	JJ	I-NP
O	272	277	study	study	NN	I-NP
O	278	281	was	be	VBD	B-VP
O	282	284	to	to	TO	B-VP
O	285	292	clarify	clarify	VB	I-VP
O	293	296	how	how	WRB	B-ADVP
O	297	307	expression	expression	NN	B-NP
O	308	310	of	of	IN	B-PP
O	311	314	p53	p53	NN	B-NP
O	315	322	protein	protein	NN	I-NP
O	323	335	participates	participate	VBZ	B-VP
O	336	338	in	in	IN	B-PP
O	339	351	angiogenesis	angiogenesis	NN	B-NP
O	351	352	,	,	,	O
O	353	356	and	and	CC	O
O	357	364	whether	whether	IN	B-SBAR
O	365	368	the	the	DT	B-NP
O	369	381	coexpression	coexpression	NN	I-NP
O	382	384	of	of	IN	B-PP
O	385	389	VEGF	VEGF	NN	B-NP
O	390	393	and	and	CC	I-NP
O	394	397	p53	p53	NN	I-NP
O	398	405	protein	protein	NN	I-NP
O	406	409	has	have	VBZ	B-VP
O	410	411	a	a	DT	B-NP
O	412	424	significance	significance	NN	I-NP
O	425	428	for	for	IN	B-PP
O	429	441	angiogenesis	angiogenesis	NN	B-NP
O	442	445	and	and	CC	O
O	446	449	the	the	DT	B-NP
O	450	469	clinicopathological	clinicopathological	JJ	I-NP
O	470	478	features	feature	NNS	I-NP
O	479	481	in	in	IN	B-PP
B-Cancer	482	492	esophageal	esophageal	JJ	B-NP
I-Cancer	493	501	squamous	squamous	JJ	I-NP
I-Cancer	502	506	cell	cell	NN	I-NP
I-Cancer	507	516	carcinoma	carcinoma	NN	I-NP
O	517	518	(	(	(	O
B-Cancer	518	521	SCC	SCC	NN	B-NP
O	521	522	)	)	)	O
O	522	523	.	.	.	O

O	524	531	METHODS	METHODS	NNS	B-NP
O	531	532	:	:	:	O
B-Tissue	533	540	Tissues	Tissue	NNS	B-NP
I-Tissue	541	548	samples	sample	NNS	I-NP
O	549	553	were	be	VBD	B-VP
O	554	559	taken	take	VBN	I-VP
O	560	564	from	from	IN	B-PP
O	565	567	60	60	CD	B-NP
O	568	576	patients	patient	NNS	I-NP
O	577	581	with	with	IN	B-PP
B-Cancer	582	592	esophageal	esophageal	JJ	B-NP
I-Cancer	593	596	SCC	SCC	NN	I-NP
O	597	602	after	after	IN	B-PP
O	603	610	surgery	surgery	NN	B-NP
O	610	611	.	.	.	O

O	612	615	The	The	DT	B-NP
O	616	626	expression	expression	NN	I-NP
O	627	629	of	of	IN	B-PP
O	630	634	VEGF	VEGF	NN	B-NP
O	635	638	and	and	CC	I-NP
O	639	642	p53	p53	NN	I-NP
O	643	650	protein	protein	NN	I-NP
O	651	653	in	in	IN	B-PP
O	654	659	these	these	DT	B-NP
B-Cancer	660	663	SCC	SCC	NN	I-NP
O	664	667	was	be	VBD	B-VP
O	668	676	examined	examine	VBN	I-VP
O	677	698	immunohistochemically	immunohistochemically	RB	B-ADVP
O	698	699	.	.	.	O

B-Tissue	700	711	Microvessel	Microvessel	NN	B-NP
O	712	719	density	density	NN	I-NP
O	720	721	(	(	(	O
O	721	724	MVD	MVD	NN	B-NP
O	724	725	)	)	)	O
O	726	729	was	be	VBD	B-VP
O	730	740	determined	determine	VBN	I-VP
O	741	743	by	by	IN	B-PP
O	744	752	counting	count	VBG	B-VP
B-Tissue	753	765	microvessels	microvessel	NNS	B-NP
O	766	768	in	in	IN	B-PP
B-Cancer	769	774	tumor	tumor	NN	B-NP
I-Cancer	775	783	sections	section	NNS	I-NP
O	784	791	stained	stain	VBN	B-VP
O	792	795	for	for	IN	B-PP
O	796	802	Factor	Factor	NN	B-NP
O	803	807	VIII	VIII	CD	I-NP
O	807	808	-	-	HYPH	B-NP
O	808	815	related	relate	VBN	I-NP
O	816	823	antigen	antigen	NN	I-NP
O	823	824	.	.	.	O

O	825	827	Ki	Ki	NN	B-NP
O	827	828	-	-	HYPH	O
O	828	830	67	67	CD	B-NP
O	831	839	labeling	label	VBG	I-NP
O	840	845	index	index	NN	I-NP
O	846	847	(	(	(	O
O	847	849	LI	LI	NN	B-NP
O	849	850	)	)	)	O
O	851	854	was	be	VBD	B-VP
O	855	865	calculated	calculate	VBN	I-VP
O	865	866	,	,	,	O
O	867	872	based	base	VBN	B-PP
O	873	875	on	on	IN	B-PP
O	876	878	Ki	Ki	NN	B-NP
O	878	879	-	-	HYPH	B-NP
O	879	881	67	67	CD	I-NP
O	882	889	antigen	antigen	NN	I-NP
O	890	904	immunostaining	immunostaining	NN	I-NP
O	904	905	,	,	,	O
O	906	908	as	as	IN	B-PP
O	909	910	a	a	DT	B-NP
O	911	924	proliferative	proliferative	JJ	I-NP
O	925	931	marker	marker	NN	I-NP
O	931	932	.	.	.	O

O	933	942	Apoptotic	Apoptotic	JJ	B-NP
O	943	948	index	index	NN	I-NP
O	949	950	(	(	(	O
O	950	952	AI	AI	NN	B-NP
O	952	953	)	)	)	O
O	954	957	was	be	VBD	B-VP
O	958	968	calculated	calculate	VBN	I-VP
O	968	969	,	,	,	O
O	970	975	based	base	VBN	B-PP
O	976	978	on	on	IN	B-PP
O	979	982	the	the	DT	B-NP
O	983	991	terminal	terminal	JJ	I-NP
O	992	1008	deoxynucleotidyl	deoxynucleotidyl	NN	I-NP
O	1009	1020	transferase	transferase	NN	I-NP
O	1020	1021	-	-	HYPH	B-VP
O	1021	1029	mediated	mediate	VBN	B-NP
O	1030	1042	deoxyuridine	deoxyuridine	NN	I-NP
O	1043	1055	triphosphate	triphosphate	NN	I-NP
O	1056	1062	biotin	biotin	NN	I-NP
O	1063	1067	nick	nick	NN	I-NP
O	1068	1071	end	end	NN	I-NP
O	1072	1080	labeling	labeling	NN	I-NP
O	1080	1081	,	,	,	O
O	1082	1084	to	to	TO	B-VP
O	1085	1093	evaluate	evaluate	VB	I-VP
O	1094	1103	apoptosis	apoptosis	NN	B-NP
O	1103	1104	.	.	.	O

O	1105	1112	RESULTS	RESULTS	NNS	B-NP
O	1112	1113	:	:	:	O
O	1114	1118	VEGF	VEGF	NN	B-NP
O	1119	1129	expression	expression	NN	I-NP
O	1130	1133	was	be	VBD	B-VP
O	1134	1142	observed	observe	VBN	I-VP
O	1143	1145	in	in	IN	B-PP
O	1146	1148	58	58	CD	B-NP
O	1148	1149	.	.	.	O
O	1149	1150	3	3	CD	B-NP
O	1150	1151	%	%	NN	I-NP
O	1151	1152	,	,	,	O
O	1153	1156	and	and	CC	O
O	1157	1160	p53	p53	NN	B-NP
O	1161	1168	protein	protein	NN	I-NP
O	1169	1179	expression	expression	NN	I-NP
O	1180	1183	was	be	VBD	B-VP
O	1184	1192	observed	observe	VBN	I-VP
O	1193	1195	in	in	IN	B-PP
O	1196	1198	61	61	CD	B-NP
O	1198	1199	.	.	.	O
O	1199	1200	7	7	CD	B-NP
O	1200	1201	%	%	NN	I-NP
O	1202	1204	of	of	IN	B-PP
O	1205	1208	the	the	DT	B-NP
O	1209	1211	60	60	CD	I-NP
O	1212	1220	patients	patient	NNS	I-NP
O	1220	1221	.	.	.	O

O	1222	1226	VEGF	VEGF	NN	B-NP
O	1227	1230	and	and	CC	I-NP
O	1231	1234	p53	p53	NN	I-NP
O	1235	1242	protein	protein	NN	I-NP
O	1243	1247	were	be	VBD	B-VP
O	1248	1261	significantly	significantly	RB	I-VP
O	1262	1273	coexpressed	coexpresse	VBN	I-VP
O	1274	1276	in	in	IN	B-PP
O	1277	1279	26	26	CD	B-NP
O	1280	1281	(	(	(	O
O	1281	1283	43	43	CD	B-NP
O	1283	1284	.	.	.	O
O	1284	1285	4	4	CD	B-NP
O	1285	1286	%	%	NN	I-NP
O	1286	1287	)	)	)	O
O	1287	1288	.	.	.	O

O	1289	1301	Histological	Histological	JJ	B-NP
B-Multi-tissue_structure	1302	1308	venous	venous	JJ	I-NP
O	1309	1317	invasion	invasion	NN	I-NP
O	1318	1319	(	(	(	O
O	1319	1320	p	p	NN	B-NP
O	1322	1326	less	less	JJR	B-NP
O	1327	1331	than	than	IN	I-NP
O	1333	1334	0	0	CD	I-NP
O	1334	1335	.	.	.	I-NP
O	1335	1337	01	01	CD	I-NP
O	1337	1338	)	)	)	O
O	1339	1342	and	and	CC	O
O	1343	1350	distant	distant	JJ	B-NP
O	1351	1361	metastasis	metastasis	NN	I-NP
O	1362	1363	(	(	(	O
O	1363	1364	p	p	NN	B-NP
O	1366	1370	less	less	JJR	B-NP
O	1371	1375	than	than	IN	I-NP
O	1377	1378	0	0	CD	I-NP
O	1378	1379	.	.	.	I-NP
O	1379	1381	05	05	CD	I-NP
O	1381	1382	)	)	)	O
O	1383	1387	were	be	VBD	B-VP
O	1388	1401	significantly	significantly	RB	I-VP
O	1402	1412	correlated	correlate	VBN	I-VP
O	1413	1417	with	with	IN	B-PP
O	1418	1421	p53	p53	NN	B-NP
O	1422	1429	protein	protein	NN	I-NP
O	1430	1440	expression	expression	NN	I-NP
O	1440	1441	.	.	.	O

O	1442	1445	The	The	DT	B-NP
O	1446	1449	two	two	CD	I-NP
O	1450	1460	parameters	parameter	NNS	I-NP
O	1461	1465	were	be	VBD	B-VP
O	1466	1470	more	more	RBR	I-VP
O	1471	1481	frequently	frequently	RB	I-VP
O	1482	1490	observed	observe	VBN	I-VP
O	1491	1493	in	in	IN	B-PP
O	1494	1497	the	the	DT	B-NP
B-Cancer	1498	1501	SCC	SCC	NN	I-NP
O	1502	1506	with	with	IN	B-PP
O	1507	1511	VEGF	VEGF	NN	B-NP
O	1511	1512	/	/	SYM	I-NP
O	1512	1515	p53	p53	NN	I-NP
O	1516	1528	coexpression	coexpression	NN	I-NP
O	1529	1533	than	than	IN	B-PP
O	1534	1536	in	in	IN	B-PP
O	1537	1542	those	those	DT	B-NP
O	1543	1550	without	without	IN	B-PP
O	1551	1554	the	the	DT	B-NP
O	1555	1567	coexpression	coexpression	NN	I-NP
O	1567	1568	.	.	.	O

O	1569	1572	The	The	DT	B-NP
O	1573	1576	MVD	MVD	NN	I-NP
O	1577	1580	and	and	CC	I-NP
O	1581	1583	Ki	Ki	NN	I-NP
O	1583	1584	-	-	HYPH	O
O	1584	1586	67	67	CD	B-NP
O	1587	1589	LI	LI	NN	I-NP
O	1590	1594	were	be	VBD	B-VP
O	1595	1608	significantly	significantly	RB	B-ADJP
O	1609	1615	higher	high	JJR	I-ADJP
O	1616	1617	(	(	(	O
O	1617	1618	p	p	NN	B-NP
O	1620	1624	less	less	JJR	B-ADJP
O	1625	1629	than	than	IN	B-PP
O	1631	1632	0	0	CD	B-NP
O	1632	1633	.	.	.	O
O	1633	1635	01	01	CD	B-NP
O	1636	1639	and	and	CC	O
O	1640	1641	p	p	NN	B-NP
O	1643	1647	less	less	JJR	B-NP
O	1648	1652	than	than	IN	I-NP
O	1654	1655	0	0	CD	I-NP
O	1655	1656	.	.	.	I-NP
O	1656	1659	001	001	CD	I-NP
O	1659	1660	)	)	)	O
O	1660	1661	,	,	,	O
O	1662	1665	and	and	CC	O
O	1666	1669	the	the	DT	B-NP
O	1670	1672	AI	AI	NN	I-NP
O	1673	1676	was	be	VBD	B-VP
O	1677	1690	significantly	significantly	RB	B-ADJP
O	1691	1696	lower	low	JJR	I-ADJP
O	1697	1698	(	(	(	O
O	1698	1699	p	p	NN	B-NP
O	1701	1705	less	less	JJR	B-NP
O	1706	1710	than	than	IN	I-NP
O	1712	1713	0	0	CD	I-NP
O	1713	1714	.	.	.	I-NP
O	1714	1717	001	001	CD	I-NP
O	1717	1718	)	)	)	O
O	1719	1721	in	in	IN	B-PP
O	1722	1725	the	the	DT	B-NP
B-Cancer	1726	1729	SCC	SCC	NN	I-NP
O	1730	1734	with	with	IN	B-PP
O	1735	1738	p53	p53	NN	B-NP
O	1739	1746	protein	protein	NN	I-NP
O	1747	1757	expression	expression	NN	I-NP
O	1758	1762	than	than	IN	B-PP
O	1763	1765	in	in	IN	B-PP
O	1766	1769	the	the	DT	B-NP
B-Cancer	1770	1773	SCC	SCC	NN	I-NP
O	1774	1781	without	without	IN	B-PP
O	1782	1784	it	it	PRP	B-NP
O	1784	1785	.	.	.	O

O	1786	1789	The	The	DT	B-NP
O	1790	1793	MVD	MVD	NN	I-NP
O	1794	1797	and	and	CC	I-NP
O	1798	1800	Ki	Ki	NN	I-NP
O	1800	1801	-	-	HYPH	O
O	1801	1803	67	67	CD	B-NP
O	1804	1806	LI	LI	NN	I-NP
O	1807	1811	were	be	VBD	B-VP
O	1812	1818	higher	high	JJR	B-ADJP
O	1818	1819	,	,	,	O
O	1820	1823	and	and	CC	O
O	1824	1827	the	the	DT	B-NP
O	1828	1830	AI	AI	NN	I-NP
O	1831	1834	was	be	VBD	B-VP
O	1835	1840	lower	low	JJR	B-ADJP
O	1841	1843	in	in	IN	B-PP
O	1844	1847	the	the	DT	B-NP
B-Cancer	1848	1851	SCC	SCC	NN	I-NP
O	1852	1856	with	with	IN	B-PP
O	1857	1861	VEGF	VEGF	NN	B-NP
O	1861	1862	/	/	SYM	I-NP
O	1862	1865	p53	p53	NN	I-NP
O	1866	1878	coexpression	coexpression	NN	I-NP
O	1879	1883	than	than	IN	B-PP
O	1884	1886	in	in	IN	B-PP
O	1887	1892	those	those	DT	B-NP
O	1893	1900	without	without	IN	B-PP
O	1901	1904	the	the	DT	B-NP
O	1905	1917	coexpression	coexpression	NN	I-NP
O	1917	1918	.	.	.	O

O	1919	1922	The	The	DT	B-NP
O	1923	1924	5	5	CD	I-NP
O	1924	1925	-	-	HYPH	I-NP
O	1925	1927	yr	yr	NN	I-NP
O	1928	1936	survival	survival	NN	I-NP
O	1937	1941	rate	rate	NN	I-NP
O	1942	1944	in	in	IN	B-PP
O	1945	1953	patients	patient	NNS	B-NP
O	1954	1958	with	with	IN	B-PP
O	1959	1962	the	the	DT	B-NP
O	1963	1975	coexpression	coexpression	NN	I-NP
O	1976	1979	was	be	VBD	B-VP
O	1980	1986	poorer	poor	JJR	B-ADJP
O	1987	1991	than	than	IN	B-PP
O	1992	1994	in	in	IN	B-PP
O	1995	1998	the	the	DT	B-NP
O	1999	2004	other	other	JJ	I-NP
O	2005	2013	patients	patient	NNS	I-NP
O	2013	2014	.	.	.	O

O	2015	2025	CONCLUSION	CONCLUSION	NN	B-NP
O	2025	2026	:	:	:	O
O	2027	2032	These	These	DT	B-NP
O	2033	2040	results	result	NNS	I-NP
O	2041	2048	suggest	suggest	VBP	B-VP
O	2049	2053	that	that	IN	B-SBAR
O	2054	2060	mutant	mutant	JJ	B-NP
O	2061	2064	p53	p53	NN	I-NP
O	2065	2075	expression	expression	NN	I-NP
O	2076	2078	is	be	VBZ	B-VP
O	2079	2089	associated	associate	VBN	I-VP
O	2090	2094	with	with	IN	B-PP
O	2095	2107	angiogenesis	angiogenesis	NN	B-NP
O	2108	2111	and	and	CC	O
O	2112	2119	distant	distant	JJ	B-NP
O	2120	2130	metastasis	metastasis	NN	I-NP
O	2131	2133	in	in	IN	B-PP
B-Cancer	2134	2144	esophageal	esophageal	JJ	B-NP
I-Cancer	2145	2148	SCC	SCC	NN	I-NP
O	2148	2149	,	,	,	O
O	2150	2153	and	and	CC	O
O	2154	2158	that	that	IN	B-SBAR
O	2159	2162	the	the	DT	B-NP
O	2163	2175	coexpression	coexpression	NN	I-NP
O	2176	2178	of	of	IN	B-PP
O	2179	2182	p53	p53	NN	B-NP
O	2183	2186	and	and	CC	I-NP
O	2187	2191	VEGF	VEGF	NN	I-NP
O	2192	2195	may	may	MD	B-VP
O	2196	2200	play	play	VB	I-VP
O	2201	2203	an	an	DT	B-NP
O	2204	2213	important	important	JJ	I-NP
O	2214	2218	role	role	NN	I-NP
O	2219	2221	in	in	IN	B-PP
O	2222	2234	angiogenesis	angiogenesis	NN	B-NP
O	2234	2235	,	,	,	O
O	2236	2239	and	and	CC	O
O	2240	2244	have	have	VBP	B-VP
O	2245	2254	important	important	JJ	B-NP
O	2255	2263	clinical	clinical	JJ	I-NP
O	2264	2276	significance	significance	NN	I-NP
O	2276	2277	.	.	.	O

